XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets    
Cash $ 2,073,849 $ 3,165,985
Prepaid expenses and other current assets 1,375,730 1,366,704
Current assets of discontinued operations 6,287,849
Total current assets 3,449,579 10,820,538
Property and equipment, net 26,242
Other assets 866,481
Non-current assets of discontinued operations 8,236,711
Total Assets 4,316,060 19,083,491
Current liabilities    
Accounts payable 1,571,831 619,568
Accrued vacation 163,701 165,040
Accrued expenses and other current liabilities 1,144,188 699,519
Warrant liabilities 92,900 788,100
Warrant liabilities - related party 2,151,892 2,834,547
Convertible debt - related party 832,100 60,197
Current liabilities of discontinued operations 3,441,198
Total current liabilities 5,956,612 8,608,169
Non-current liabilities of discontinued operations 1,708,732
Total liabilities 5,956,612 10,316,901
Commitments and Contingencies (Note 10)
Qualigen Therapeutics, Inc. stockholders’ equity (deficit):    
Common stock, $0.001 par value; 225,000,000 shares authorized; 5,052,463 and 4,210,737 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively 42,952 42,110
Additional paid-in capital 112,668,631 110,528,050
Accumulated other comprehensive income 50,721
Accumulated deficit (114,352,135) (103,385,172)
Total Qualigen Therapeutics, Inc. stockholders’ equity (deficit) (1,640,552) 7,235,709
Noncontrolling interest 1,530,881
Total Stockholders’ Equity (deficit) (1,640,552) 8,766,590
Total Liabilities & Stockholders’ Equity (Deficit) $ 4,316,060 $ 19,083,491